

200400796A (論文集)

厚生労働科学研究費補助金

難治性疾患克服研究事業

難治性自己免疫性肝疾患の画期的治療法の
開発に関する臨床研究

平成16年度

論文集

主任研究者

石橋大海

平成17(2005)年3月

目 次

1. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. *Gastroenterology*. 2004;127(2):485-492 1
2. Kamihira T, Shimoda S, Nakamura M, Yokoyama T, Takii Y, Kawano A, Handa M, Ishibashi H, Gershwin ME, Harada M. Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases. *Hepatology*. 2005;41(1):151-159 9
3. Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, Daikoku M, Yano K, Matsumoto T, Migita K, Yatsushashi H, Ito M, Masaki N, Adachi H, Watanabe Y, Nakamura Y, Saoshiro T, Sodeyama T, Koga M, Shimoda S, Ishibashi H. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. *J Hepatol*. 2005;42(3):386-392 18
4. Takii Y, Nakamura M, Ito M, Yokoyama T, Komori A, Nakao R, Fukuda M, Kusumoto K, Nagaoka S, Yano K, Abiru S, Matsumoto T, Manabu D, Migita K, Yatsushashi H, Harada M, Ishibashi H. Enhanced-expression of type I interferon and toll-like receptor-3 in the liver of primary biliary cirrhosis. *Lab Invest*. 2005;(in press)
5. Ichiki Y, Shimoda S, Ishibashi H, Gershwin ME. Is primary biliary cirrhosis a model autoimmune disease? *Autoimmun Rev*. 2004;3(4):331-336 25
6. Ichiki Y, Leung PSC, Ishibashi H, Coppel RL, Ansari AA, Gershwin AA: Mitochondria and autoimmunity in primary biliary cirrhosis. *Mitochondrion*. 2004;4:743-753 31
7. Ishibashi H, Ichiki Y, Kamihira T, Shimoda S. T Cell Immunity in Primary Biliary Cirrhosis. *Mucosal Immunology Update*. 2004;14:10-12 42
8. Komori A, Ishibashi H. Hen and egg, you mitochondria! PBC revisits mitochondria again. *Hepatol Res*. 2005;31(1):1-2 45
9. Ichiki Y, He XS, Shimoda S, Ishibashi H, Keefe EB, Rossaro L, Gershwin ME. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. *Autoimmun Rev*. 2005;4(2):82-95 47
10. Ito M, Ishibashi H. Interobserver variation in assessing small bile duct lesions in PBC, CVH, and AIH. *J Gastroenterol*. 2005;40(2):223-224 61
11. Ichiki Y, Bowlus C, Shimoda S, Ishibashi H, Vierling J, Gershwin ME: T cell immunity and Graft-versus-host disease (GVHD), *Autoimmunity Rev*. 2005;(in press)
12. 小森敦正, 中村 稔, 石橋大海: 特集 Biliary Cell Lineage 3. 獲得免疫の立場から. 肝臓. 2004; 45(12): 646-649 63
13. 石橋大海: 原発性胆汁性肝硬変の診断と治療の最前線. 治療. 2004; 86(9):2555-2560 ... 67
14. 石橋大海: 自己免疫性肝疾患の診療の進歩. 原発性胆汁性肝硬変—原因究明の進歩—. 日本消化器病学会. 2005; 102(1):10-16 73

15. 石橋大海：特集；肝臓の臨床最前線，肝疾患の病態と対策，「自己免疫性肝疾患」，総合臨床，2005;54(3):560-566 80
16. 瀧井 康，伊東正博，石橋大海：肝生検診断Ⅱ－非腫瘍性疾患－ 内科医が肝生検診断に求めるもの。病理と臨床。2005；23(3):228-234 87
17. Migita K, Miyashita T, Ishibashi H, Maeda Y, Nakamura M, Yatsushashi H, Ida H, Kawakami A, Aoyagi T, Kawabe Y, Eguchi K. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol. 2004 Sep;137(3):612-616 94
18. Migita K, Abiru S, Nakamura M, Ishibashi H. Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro. FEBS Lett 2004;2;569(1-3):235-239 99
19. Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsushashi H, Ishibashi H, Eguchi K. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology (Oxford). 2005;44(4):443-448 104
20. Kogawa H, Migita K, Ito M, Takii Y, Daikoku M, Nakao M, Kimura H, Hamada H, Miyashita T, Ezaki H, Nakamura M, Yatsushashi H, Eguchi K, Ishibashi H. Idiopathic portal hypertension associated with systemic sclerosis and Sjögren's syndrome. Clin Rheumatology 2005;(in press)
21. Ito Y, Eguchi S, Kamohara Y, Inuo H, Yamanouchi K, Okudaira S, Yanaga K, Furui J, Kanematsu T. Influence of serum from rats with fulminant hepatic failure on hepatocytes in a bioartificial liver system. Int J Artif Organs. 2004;27(4):303-310 112
22. Tsutsumi R, Kamohara Y, Eguchi S, Azuma T, Fujioka H, Okudaira S, Yanaga K, Kanematsu T. Selective suppression of initial cytokine response facilitates liver regeneration after extensive hepatectomy in rats. Hepatogastroenterology. 2004;51(57):701-704 120
23. Onaga M, Ido A, Hasuike S, et al. Enhanced expression of growth factors and imbalance between hepatocyte proliferation and apoptosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol Res. 2004;28:94-101 124
24. Ido A, Moriuchi A, Kim I, Numata M, Nagata-Tsubouchi Y, Hasuike S, Uto H, Tsubouchi H. Pharmacokinetic study of recombinant human hepatocyte growth factor administered in a bolus intravenously or via portal vein. Hepatol Res. 2004;30(3):175-181 ... 132
25. Hasuike S, Ido A, Uto H, et al. Hepatocyte growth factor accelerates the proliferation and differentiation of hepatic oval cells in a 2-acetylaminofluorene/partial hepatectomy model in rats. J Gastroenterol Hepatol. 2005;(in press)
26. Nishimura Y, Chen Y-Z, Uemura Y, Tanaka Y, Tsukamoto H, Kanai T, Yokomizo H, Yun C, Matsuoka T, Irie A, and Matsushita S. Degenerate recognition and response of human CD4+ Th cell clones: Implications for basic and applied immunology. Mol Immunol. 2004;40:1089-1094 139

27. Ohyama H, Kato N, Takeuchi K, Uemura Y, Nishimura F and Matsushita S. Monocytes of distinct clinical types of leprosy are differentially activated by crosslinking class II HLA molecules to secrete IL-12. *APMIS* 2004;112:271-274 145
28. Matsushita S, Ohyama H, Kudo H, Tabata H and Matsuoka T. HLA-mediated signaling via HLA-peptide-TCR complex determines immune responses of antigen-presenting cells. *Current Topics in Peptide & Protein Research*.2004;6:1-20 149
29. 松下 祥 : 抗原特異的免疫療法. *医学のあゆみ*. 2004;208(9) :778-783 169
30. 松下 祥 : HLA による免疫応答の制御. *ゲノム医学*. 2004;4:453-458 175
31. 松下 祥 : Th2 応答とアジュバント. *感染・炎症・免疫*. 2004;34(3) :192-198 181
32. 松下 祥 : MHC クラス II 分子を介したシグナル伝達機構. *臨床免疫*. 2004;42(4) :455-463 188
33. 松下 祥 : Th2 アジュバント. *アレルギー科*. 2004;18(3) :239-246 197
34. Ohyama H, Ogata K, Takeuchi K, Namisato M, Fukutomi Y, Nishimura F, Naruishi H, Ohira T, Hashimoto K, Liu T, Suzuki M, Uemura Y, Matsushita S. Polymorphism of the 5' flanking region of the IL-12 receptor beta2 gene partially determines the clinical types of leprosy through impaired transcriptional activity. *J. Clin. Pathol.* 2005;(in press)
35. Matsushita S, Liu T-Y and Uemura Y. Adjuvants that enhance Th2 or Tr responses. *Allergol. Int.* 2005;(in press)
36. 松下 祥 : T細胞シグナル伝達における HLA クラス II 分子の役割. *炎症と免疫* 2005;(in press)
37. Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, Masuda A, Yoshikai Y, Takamoto M, Sugane K, Matsuo S, Shimada Y, Matsuguchi T: A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. *J. Clin. Invest.* 2004; 114: 857-866 205
38. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA: Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression. *Mol. Cell. Biol.* 2004;24:4743-4756 215
39. Abe T, Arai T, Ogawa A, Hiromatsu T, Masuda A, Matsuguchi T, Nimura Y, Yoshikai Y. : Kupffer cell-derived interleukin 10 is responsible for impaired bacterial clearance in bile duct-ligated mice. *Hepatology* 2004;40:414-423 229
40. Masuda A, Yoshikai Y, Kume H, Matsuguchi T. : The interaction between GATA proteins and activator protein-1 promotes the transcription of IL-13 in mast cells. *J Immunol.* 2004;173:5564-5573 239
41. Musikacharoen T, Oguma A, Yoshikai Y, Chiba N, Masuda A, Matsuguchi T. : Interleukin-15 induces IL-12 receptor {beta}1 gene expression through PU.1 and IRF 3 by targeting chromatin remodeling. *Blood* 2005;105:711-720 249

42. Yamamoto S, Sato Y, Ichida T, Kurosaki I, Nakatsuka H, and Hatakeyama K. Acute renal failure during the early postoperative period in adult living-related donor liver transplantation. *Hepatogastroenterology*. 2004;51(60):1815-1819 259
43. Sato Y, Watanabe H, Ichida T, Yamamoto S, Nakatsuka H, Oya H, Kameyama H, Watanabe T, Shimamura K, Abo T, and Hatakeyama K. Wall shear stress and intrahepatic leukocytes of graft in living related donor liver transplantation. *Hepatogastroenterology*. 2004; 51(56):329-333 264
44. Takeishi T, Sato Y, Ichida T, Yamamoto S, Hirano K, Kobayashi T, Watanabe T, and Hatakeyama K. Rapid progressive hepatitis C after liver transplantation: a case report. *Transplant Proc*. 2004;36(8):2304 269
45. Ikai T, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma T, Okita K, Omata M, Takayasu K, and Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. *Cancer*. 2004; 101(4):796-802 270
46. Sato Y, Ichida T, Watanabe H, Yamamoto S, Abo T, and Hatakeyama K. Macrochimerism of donor type CD56+CD3+ T cells in donor specific transfusion via portal vein following living related donor liver transplantation. *Hepatogastroenterology*. 2003; 50(54):2161-2165 277
47. 山際訓、市田隆文 : インターフェロン抵抗性に關与する宿主免疫關連因子. *肝胆膵* 2004; 49(6):1039-1046 282
48. Yamashita T, Honda M, Takatori H, Nishino R, Hoshino N, Kaneko S. Genome-wide transcriptome mapping analysis identifies organ-specific gene expression patterns along human chromosomes. *Genomics*. 2004;84(5):867-875. 290
49. Honda M, Shimazaki T, Kaneko S. La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. *Gastroenterology*. 2005;128(2):449-462 299
50. Yamori M, Yoshida M, Watanabe T, Shirai Y, Iizuka T, Kita T, Wakatsuki Y. Antigenic activation of Th1 cells in the gastric mucosa enhances dysregulated apoptosis and turnover of the epithelial cells. *Biochem Biophys Res Commun*. 2004;316(4):1015-1021 313
51. Watanabe T, Chiba T, Wakatsuki Y. Portal Vein Tolerance and Development of Regulatory CD4 T cells in the liver. *Mucosal Immunology Update*. 2004;4:2-6 320
52. Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. *Hepatol Res*. 2004;29(3):153-159 325
53. 田中 篤. ミトコンドリア抗体 : 最近の展開. *肝胆膵*. 2004;49(2):161-167 332
54. Hiroto Kita, Michio Imawari, M. Eric Gershwin, Cellular Immune Response in Primary Biliary Cirrhosis *Hepatology Research* 2004;28:12-17 339

55. Hiroto Kita, Xiao-Song He, M. Eric Gershwin. Autoimmunity and Environmental Factors in the Pathogenesis of Primary Biliary Cirrhosis, *Annals of Medicine* 2004;36:72-80 345
56. Hiroto Kita: Are Antibodies to Carbonic Anhydrase Disease Specific Marker? *Hepatology Research (Editorial)* 2004;30:238-239 354
57. 喜多宏人: PBCの発症機序、細胞生物学講座「細胞」. 2004;36(5):207-211 356
58. 喜多宏人、M.E.Gershwin: 原発性胆汁性肝硬変における樹状細胞の自己抗原提示機序「Minophagen Medical Review」. 2004;49:218-221 361
59. 喜多宏人: 抗ミトコンドリア抗体<特集>検査値を読む, 「内科」. 2004;93(6):1242 ... 365
60. 喜多宏人: PDC-E2 とキラーT細胞. PBC, PSC の最近の話題, 「肝胆膵」. 2004;49(2):179-183 366
61. 喜多宏人: CD8陽性自己反応性T細胞の活性化を抗原特異的に阻害するT細胞受容体アンタゴニスト 特集 II 肝疾患における免疫療法, 「消化器科」. 2004;36(5):541-544 371
62. 大曲勝久、角川淑子、石原 康、河野 茂: 原発性胆汁性肝硬変の経過観察における「MESACUP-2 テストミトコンドリア M2」測定 of 臨床的意義. -蛍光抗体間接法との比較検討-, *医学と薬学* 2003;50(4):543-550 375
63. 中村陽子: 自己免疫性肝疾患を見逃さないために-合併する肝外自己免疫疾患の特徴- *Modern Physician* 2003 ; 23(4) : 485-487 383
64. Marzioni M, Glaser S, Francis H, Marucci L, Benedetti A, Alvaro D, Taffetani S, Ueno Y, Roskams T, Phinizy JL, Venter J, Fava G, Lesage GD, Alpini G. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. *Gastroenterology* 2005;128(1):121-137 386
65. Marienfeld C, Yamagiwa Y, Ueno Y, Chiasson V, Brooks L, Meng F, Patel T. Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. *Gastroenterology* 2004;127(6):1787-1797 403
66. LeSage GD, Alvaro D, Glaser S, Francis H, Marucci L, Roskams T, Phinizy JL, Marzioni M, Benedetti A, Taffetani S, Barbaro B, Fava G, Ueno Y, Alpini G. Alpha-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca(2+)- and PKC-dependent stimulation of cAMP. *Hepatology* 2004;40(5):1116-1127 414
67. Gigliozzi A, Alpini G, Baroni GS, Marucci L, Metalli VD, Glaser SS, Francis H, Mancino MG, Ueno Y, Barbaro B, Benedetti A, Attili AF, Alvaro D. Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. *Gastroenterology* 2004;127(4):1198-1209. 426
68. Francis H, Glaser S, Ueno Y, Lesage G, Marucci L, Benedetti A, Taffetani S, Marzioni M, Alvaro D, Venter J, Reichenbach R, Fava G, Lynne Phinizy J, Alpini G. cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. *J Hepatol.* 2004;41:528-537 438

69. Harada K, Ohba K, Ozaki S, Isse K, Hirayama T, Wada A, Nakanuma Y. Peptide Antibiotic Human Beta-Defensin-1 and -2 Constitute Antimicrobial Defense in the Intrahepatic Biliary Tree. *Hepatology*. 2004;40(4):925-932 448
70. Isse K, Harada K, Zen Y, Kamihira T, Shimoda S, Harada M, Nakanuma Y. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. *Hepatology*. 2005;41(3):506-516 456
71. Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine induced down-regulation of PPAR γ in biliary cells relates to cholangitis in primary biliary cirrhosis. *Hepatology* 2005;(in press)
72. 原田憲一, 中沼安二. Biliary cell lineage. 2. 自然免疫の観点から. *肝臓*. 2004;45(12):642-645 467
73. 原田憲一, 中沼安二. 細菌/ウイルス感染とPBC. *肝胆膵*. 2004;49(2):147-157 471
74. Ishikawa F, Shimoda S, *et al*. Human cord blood- and bone marrow-derived CD34+ cells regenerate gastrointestinal epithelial cells. *Faseb J* 2004;18:1958-1960 482
75. Haro T, Shimoda K, Kakumitsu H, Kamezaki K, Numata A, Ishikawa F, Sekine Y, Muromoto R, Matsuda T, Harada M. Tyrosine kinase 2 interacts with and phosphorylates receptor for activated C kinase-1, a WD motif-containing protein. *J Immunol*. 2004;173(2):1151-1157 485
76. Ishikawa F, Yasukawa M, Yoshida S, Nakamura K, Nagatoshi Y, Kanemaru T, Shimoda K, Shimoda S, Miyamoto T, Okamura J, Shultz LD, Harada M. Human cord blood- and bone marrow-derived CD34+ cells regenerate gastrointestinal epithelial cells. *FASEB J*. 2004;18(15):1958-1960 492
77. Nakamura T, Ishikawa F, Sonoda KH, Hisatomi T, Qiao H, Yamada J, Fukata M, Ishibashi T, Harada M, Kinoshita S. Characterization and distribution of bone marrow-derived cells in mouse cornea. *Invest Ophthalmol Vis Sci*. 2005;46(2):497-503 508
- 書籍
78. Shimoda S, Nishio A, Ishibashi H, Gershwin ME: Primary Biliary Cirrhosis Bench to Bedside, Chapter 28. *The Pathophysiology of the Biliary Epithelia*, edited by Gianfranco Alpini, Domenico Alvaro, Marco Marziani, Gene LeSage, and Nicholas LaRusso. LANDES BIOSCIENCE, GEORGETOWN, EUREKAH.COM, AUSTIN, 454p, 2004:330-348 515
79. Ishibashi H, Shimoda S, Gershwin ME. The immune response to mitochondrial autoantigens. *Seminars in Liver Disease*. 2005;(in press)
80. 小森敦正, 中村 稔, 石橋大海: 原発性胆汁性肝硬変/原発性硬化性胆管炎. *肝疾患と免疫*. 各務伸一編. 医薬ジャーナル社, 大阪, 2005;179:133-140 534
81. 石橋大海: 「原発性胆汁性肝硬変 Primary biliary cirrhosis: PBC」の項, 「自己免疫性肝炎 Autoimmune hepatitis: AIH」の項, 専門医のための消化器病学, 医学書院. 2005;(in press)
82. 松下 祥: 免疫遺伝学、福田 健 編: 「総合アレルギー学」, 南江堂 (東京) 52-59;2004 542

83. 松下 祥 : 抗原の処理と提示、烏山一編 : 「免疫学イラストマップ」, 羊土社 (東京), 72-82; 2004
..... 550
84. 松下 祥 : 抗原認識、花岡炳雄編 : 「臨床分子細胞生物学」, メディカルレビュー社 (東京)
2005; (in press)
85. 成田弥生、植村靖史、松下 祥 : リンパ球を用いた診断法の可能性, 菊地博達編 : 「悪性高熱」,
克誠堂出版 (東京), 2005; (in press)

Primary Biliary Cirrhosis in Monozygotic and Dizygotic Twins: Genetics, Epigenetics, and Environment

CARLO SELMI,*† MARLYN J. MAYO,§ NANCY BACH,|| HIROMI ISHIBASHI,¶ PIETRO INVERNIZZI,† ROBERT G. GISH,* STUART C. GORDON,** HARLAN I. WRIGHT,†† BRUCE ZWEIBAN,§§ MAURO PODDA,† and M. ERIC GERSHWIN*

*Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, California; †Division of Internal Medicine, Department of Medicine, Surgery, and Dentistry, University of Milan, Milan, Italy; §Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas; ||Department of Liver Diseases, Mt. Sinai University, New York, New York; ¶Clinical Research Center, National Nagasaki Medical Center, Nagasaki, Japan; †Department of Transplant, Sutter California Pacific Medical Center, San Francisco, California; **Division of Gastroenterology and Hepatology, William Beaumont Hospital, Royal Oak, Michigan; ††Nazih Zuhdi Transplant Institute, Oklahoma City, Oklahoma; and §§Division of Gastroenterology, Southern California Kaiser Permanente Hospital, Panorama City, California

Background & Aims: There is growing evidence that the interplay of genetic susceptibility and environmental factors leads to primary biliary cirrhosis (PBC). In particular, family members of an affected individual have up to a 100-fold higher risk of developing PBC. Although concordance rates for identical twins in other autoimmune diseases range between 25% and 50%, there are no such data on PBC. Accordingly, we evaluated the concordance of PBC in a genetically defined population of twin sets and evaluated the clinical characteristics between concordant subjects. **Methods:** We identified 16 pairs of twins within a 1400-family cohort followed up by several centers worldwide, evaluated the diagnosis of PBC in all individuals, and determined the zygosity of sets reported as identical by the analysis of 2 highly variable HLA class II regions and 5 short tandem repeats. **Results:** Eight of 16 sets of twins were monozygotic. In 5 of 8 monozygotic twin sets, both individuals had PBC (pairwise concordance rate, 0.63). Among the dizygotic twins ($n = 8$), no set was found to be concordant for PBC. Interestingly, the age at onset of disease was similar in 4 of 5 concordant sets of monozygotic pairs; however, there were differences in natural history and disease severity. **Conclusions:** The concordance rate of PBC in identical twins is among the highest reported in autoimmunity. However, discordant pairs were identified. The data show not only the role of genetics but also emphasize that either epigenetic factors and/or environment play a critical role.

Primary biliary cirrhosis (PBC) is an autoimmune liver disease of unknown origin characterized by chronic inflammation and destruction of intrahepatic bile ducts, eventually leading to liver cirrhosis.¹ The prevalence of PBC varies in different geographic areas.^{2,3} Xenobiotics have been suggested as environmental factors in loss of tolerance, leading to autoimmunity.⁴ Although

a number of genetic factors have been suggested in population and family studies, no definitive genetic association with the development of the disease or its outcome has been found.⁵

Disease concordance rates (CRs) (roughly defined as the proportion of affected pairs concordant for the disease) in monozygotic (MZ) (who are genetically identical but also share the environmental background) and dizygotic (DZ) (who share the environmental factors but not the genetic background) twin pairs are powerful tools to estimate the weight of genetic and environmental factors in the susceptibility to multifactorial diseases. In autoimmune diseases other than PBC, CRs in MZ twins vary widely (Table 1) and, with the exception of celiac disease, have been reported to be <0.50 in large cross-sectional studies. Data concerning PBC concordance in MZ twins are limited to 2 reports. In 1973, the case of twin sisters both with PBC was reported without ascertaining zygosity.⁶ A more recent report described a pair of identical twins discordant for the disease,⁷ although the monozygosity of the set has been debated⁸ and the healthy twin was found to have low-titer antimitochondrial antibodies (AMA). In this study, we studied the CRs among 8 genetically proven MZ and 8 DZ twin sets.

Abbreviations used in this paper: AMA, antimitochondrial antibodies; CR, concordance rate; DZ, dizygotic; MZ, monozygotic; PBC, primary biliary cirrhosis; PCR, polymerase chain reaction; STR, short tandem repeat.

© 2004 by the American Gastroenterological Association
0016-5085/04/\$30.00

doi:10.1053/S0016-5085(04)00841-8

Table 1. Evidence of Concordant Occurrence of Autoimmune Diseases in MZ and DZ Twins

	MZ concordance	DZ concordance
PBC ⁷	Discordant pair reported	—
Primary sclerosing cholangitis ⁴⁷	Concordant pair reported	—
Systemic lupus erythematosus ⁴⁸	0.24	0.02
Sjögren's syndrome ⁴⁹	Concordant pair reported	—
Type 1 diabetes mellitus ^{40,50-52}	0.21-0.70 ^a	0.00-0.13
Rheumatoid arthritis ⁵³⁻⁵⁵	0.12-0.15	0.035-0.036
Graves' disease ^{56,57}	0.17-0.29	0.00-0.02
Multiple sclerosis ^{58,59}	0.25-0.31 ^a	0.03-4.7
Celiac disease ^{43,60}	0.75-0.83	0.11

NOTE. Pairwise concordance rates (ranges) are reported when available.

^aPairwise concordance rate over 7.5 years or longer.

Patients and Methods

Subjects

As part of a long-term effort, our laboratory has collaborated with tertiary referral centers as well as the PBCers, an Internet group of patients. This database includes information on the presence of twins within families that have at least one index case of PBC. At the time this study was initiated, we estimate that there were approximately 1400 families in the database; within this group, we requested information as to whether any sets of twins were present. The investigators involved contacted the twins directly to determine whether they were interested in participating in this study. Through this effort, we identified 16 twin sets in which a diagnosis of PBC was encountered. There were no twins who declined participation in the study. To confirm the diagnosis, a protocol explaining the nature of the study and internationally accepted criteria for the diagnosis of PBC¹ was required. There were 8 of 16 twin sets that were believed to be identical. There were 8 additional sets referred to us as being nonidentical, based on either different sex or previously obtained data. To verify the zygosity of those twins referred to us as identical, blood samples were obtained and studied as described below. Clinical

data were also obtained. A definite or probable diagnosis of PBC was made when at least 2 of the 3 following criteria were fulfilled: serum AMA positivity at a titer greater than 1:40, elevated serum alkaline phosphatase level for longer than 6 months, and diagnostic liver histology.⁹ AMA status was determined by indirect immunofluorescence on Hep-2 cell lines, and a titer greater than 1:40 was considered AMA positive. Liver biopsy was not performed in asymptomatic subjects not presenting other diagnostic criteria. This study protocol respected the ethical guidelines of the 1975 Declaration of Helsinki and subsequent modifications; all patients gave their written consent at the referring center.

DNA and Sera Isolation

Peripheral blood samples were obtained for DNA isolation in 10-mL tubes containing EDTA. Genomic DNA was obtained from peripheral blood lymphocytes using the Qiagen BloodAmp Maxi Kit (Qiagen, Valencia, CA) and stored at -20°C before use.

Clinical Characteristics of Subjects

Clinical data were obtained from the referring centers; further, all physicians were asked to reevaluate the diagnosis of PBC and complete a comprehensive form describing the history and clinical data of each subject. Briefly, 2 of 3 conditions (elevated serum alkaline phosphatase level for longer than 6 months, positivity for serum AMA, or diagnosis by histology) had to be fulfilled to confirm the diagnosis of PBC. Biochemical, serologic, histologic, and ultrasonographic characteristics of patients at the time of blood sampling were also required. Other autoimmune conditions were rigorously evaluated by physicians in each case.

Determination of Zygosity

The zygosity of 8 twin pairs referred as identical was verified by DNA typing of 2 highly variable HLA class II regions and 5 short tandem repeats (STRs) localized on different chromosomes (listed in Table 2). HLA typing was performed at the University of Texas Southwestern in Dallas using a sequence-specific primer molecular method to identify DRB1 alleles present at an intermediate resolution level.¹⁰ The presence of DRB3 (DR52), DRB4 (DR53), and DRB5 (DR51) was also determined to be positive or negative. The analysis of STR polymorphisms was performed at the University of California at Davis. In both cases, researchers were blind with

Table 2. Primer Sequences, Size Ranges, and Annealing Temperature Used for the Study of Microsatellite STR Polymorphisms

Locus	Size range (base pairs)	Annealing temperature (°C)	Forward primer	Reverse primer
D4S1647	132-156	45	TATTTCCAACACCCCTGCTA	AAGCAAAGAGGATTGAAAGTG
D5S815	252-296	45	TGGTATACCTGTGTAGCAAATTACA	TGCCATGATTGTTAAGTTTCC
D22S683	160-196	45	AACAAAACAAAACAAAACAAAACA	GGTGGAATGCCTCATGTAG
D7S796	162-198	55	TTTTGGTATTGCCATCCTA	GAAAGGAACAGAGACAGGG
D21S1910	194-266	55	TTCTCTGGAATAAACGTGG	CACGGCAAAGTAGTATTTAATG

respect to the identity of subjects. Genotypes for STR polymorphisms were determined using polymerase chain reaction (PCR) amplification of 10 ng of genomic DNA in 25- μ L total volume reactions. The PCR solution included 10 mmol/L deoxynucleoside triphosphate mix, 25 mmol/L $MgCl_2$ solution, 10 \times PCR Gold Buffer, 1 U AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA), 20 μ mol/L Human MapPair Primers (Invitrogen, Carlsbad, CA), and deoxyribonuclease/ribonuclease-free water up to a 25- μ L volume. Table 2 shows the sequences of the primer sets, the expected size range of the amplified sequence, and the appropriate annealing temperature. Forward primers were labeled with adenosine triphosphate (γ -33P) (Perkin-Elmer, Boston, MA) using a T4 Polynucleotide Kinase system (Invitrogen). Amplification was performed using a Programmable Thermal Controller (MJ Research Inc., Waltham, MA) under the following conditions: 10-minute denaturation at 94°C, 9 cycles of 45 seconds at 94°C, 45 seconds at 60°C to 52°C ($-1^\circ C$ per cycle), 60 seconds at 72°C, 35 cycles of 45 seconds at 94°C, 45 seconds at annealing temperature appropriate for each primer (Table 2), and 60 seconds at 72°C, followed by 7 minutes at 72°C. On completion of PCR, 1 μ L of product was taken and added to 15 μ L of dye and water and heated for 5 minutes at 95°C. Finally, 3 μ L of product/dye solution was run onto a 7% polyacrylamide Bio-Rad Sequencing Gel (Bio-Rad Laboratories, Inc., Hercules, CA) for 3 hours at 60 W and then transferred to a Molecular Dynamics Phosphor Screen (Amersham Biosciences, Piscataway, NJ). Gel results were analyzed using ImageQuaNT by Molecular Dynamics (Amersham Biosciences). Figure 1 shows the visual results obtained with one set of primers (STR D22S683).

CR in MZ and DZ Twins

Two types of CR for PBC were assessed for MZ and DZ twins. Pairwise CRs were estimated as described by Emery¹¹ and MacGregor¹² (Pairwise CR = Number of Concordant Pairs/Number of Total Pairs). This CR simply provides the proportion of affected pairs concordant for the disease. To estimate the risk for a twin to be affected given that his or her cotwin has been diagnosed with PBC, we also calculated the proband-wise CR as follows: Proband-wise CR = $2 \times$ the Number of Concordant Pairs / ($2 \times$ the Number of Concordant Pairs + the Number of Discordant Pairs).

Results

Diagnosis of PBC and Determination of Zygosity

Based on internationally accepted criteria,^{1,9} we confirmed the diagnosis in 21 of 21 patients previously diagnosed with PBC by their referring physicians. In the remaining 11 of 11 individuals, we confirmed the absence of PBC, once again as noted by their referring physicians. No doubtful diagnosis of PBC (i.e., only one criterion fulfilled) was encountered. Results obtained by

genetic analysis (combining HLA and STR independent typings) confirmed the monozygosity of the 8 twin pairs referred as identical. In our series, therefore, 8 MZ (all female; age range, 38–77 years) and 8 DZ (4 female and 4 male-female pairs; overall age range, 31–60 years) twin sets were found.

PBC in MZ and DZ Twin Sets

Among MZ twins (Table 3), PBC was diagnosed in both individuals within 5 pairs of twins; the other 3 sets were discordant for the disease, thus leading to a pairwise CR of 0.63 and a proband-wise CR of 0.77. When the 8 pairs of DZ twins were analyzed, none of them presented concordance for occurrence of PBC, leading to null pairwise CR and proband-wise CR.

In 3 of the 5 concordant MZ twin pairs (Table 4, sets 3–5), there were no significant differences in serology, disease stage, or accompanying symptomatology. The age at onset of PBC was similar in 4 of 5 sets of twins; in only one case (set 5), the 2 sisters were diagnosed with PBC within 5 years. In one case (set 2), the twins had significantly different clinical progressions, with one individual (A) presenting signs of stable disease for more than 13 years of follow-up and the other (B) requiring liver transplantation 8 years after the diagnosis of end-stage PBC. In another set (set 5), 2 different stages of PBC were observed at liver histology. We also note that the duration of follow-up in the 3 discordant DZ twins affected by PBC was between 5 and 12 years; the characteristics of the affected twins are presented in Table 5. No clear environmental differences could be identified between affected and nonaffected MZ twins.

Discussion

A large number of genetic and epidemiologic studies in PBC suggest a variable prevalence of disease in different geographic areas as well as a significant risk for development of disease in first-degree relatives of an affected subject.^{2,3,13} In addition, the relatives of affected diseased individuals often develop PBC within a short time of the first case, suggesting environmental influences.¹³ A large number of discrete genetic alleles have been studied in PBC, but there has not been definitive evidence of a specific association. Importantly, the strong association of HLA observed in other autoimmune diseases has not been found in PBC, and often the data are either conflicting or restricted to a specific geographic area.^{14–26} Other polymorphisms have been suggested to confer susceptibility or influence progression of PBC, but again these data are either debated, conflicting, or nonconclusive.^{27–30}




Figure 1. PCR products for the STR polymorphism (range, 160–196 base pairs) at D22S683 are shown for a group of representative MZ and DZ twins.

The frequency of MZ twinning has been relatively constant over the past 5 decades and is estimated to be 4 in 1000 births, whereas DZ rates change over time and are influenced by several factors.³¹ We may therefore infer that the 8 MZ twin sets described herein reflect approximately 2000 patients with PBC, an estimate compatible with the 1400 families we identified. Studies comparing the CR between MZ and DZ twins are pow-

Table 3. Pairwise and Proband-wise CRs for PBC Observed Among MZ and DZ Twins

	Sex	Concordant for PBC	Proband-wise CR	Pairwise CR
MZ twin pairs (n = 8)	8/8 F/F	5/8	0.63	0.77
DZ twin pairs (n = 8)	4/8 F/F	0/4	0	0
	4/8 F/M	0/4	0	0

Table 4. Clinical Characteristics of MZ Twin Pairs Concordant for PBC

	Set 1		Set 2		Set 3		Set 4		Set 5	
	A	B	A	B*	A	B	A	B	A	B
Ethnicity	Asian		White		White		White		White	
Country of residence	United States		United States		United States		United States		Ireland	
Birth year	1925		1952		1964		1946		1953	
Occupation	Housewife	Housewife	Clerical	Consultant	Housewife	Housewife	Nurse	Publisher	Housewife	Housewife
Year of diagnosis (age [yr])	1990/65	1990/65	1990/38	1988/36	1997/33	1997/33	1995/49	1995/49	1998/55	2003/60
Status	Alive	Alive	Alive	Orthotopic liver transplantation (1996)	Alive	Alive	Alive	Alive	Alive	Alive
Follow-up (yr)	13	12	13	8	6	6	8	8	6	1
Symptoms	Pruritus	Fatigue	None	Liver failure	Fatigue	Fatigue	Fatigue	Fatigue	Pruritus, fatigue	Pruritus, fatigue
Latest histologic stage (yr)	III (1997)	II (1993)	I (1990)	IV (1996)	III (1999)	II-III (1997)	II (2000)	III (1995)	I (1998)	II-III (2003)
Endoscopic signs of portal hypertension	Mild portal hypertensive gastropathy	None	None	Esophageal varices	—	—	None	None	None	Not done
Associated autoimmune conditions	Autoimmune hepatitis	Sicca	Sicca	Sicca	None	Sicca	Hypothyroidism	Hypothyroidism	Raynaud's syndrome	None

NOTE. All subjects were female and AMA positive.
 *All clinical data refer to the condition before orthotopic liver transplantation (1996).

erful tools to evaluate the role of genetic and environmental factors in determining the susceptibility to diseases that appear as multifactorial. However, it should be emphasized that the immune response depends on somatic mutation and such events are stochastic. In other words, there is evidence that the immune response of identical twins may not be identical, as recently described in multiple sclerosis.³²

Increasing evidence, however, has been provided to challenge the traditional view of MZ twins as being "identical." Such evidence derives from studies on the effects of intrauterine characteristics as well as on epige-

netics. Briefly, in the former case, it has been shown that there may be, during an antenatal infection, a differential involvement of twin fetuses.³³ Additionally, twins may be different based on the timing of the division of the fertilized egg into 2 separate embryos and ultimately the sharing of the amniotic sac, or chorionic and placental formation.³³ These specific environmental factors have been shown to be involved in the determination of the phenotype of the fetuses, albeit preserving their identical genome background. Furthermore, epigenetic alterations, indicating differences in the layer of protein and chemicals surrounding the DNA and particularly the

Table 5. Clinical Characteristics of Affected Subjects From MZ Sets Discordant for PBC

	Affected twin from discordant MZ sets ^a		
	5A	6A	7A
Sex	Female	Female	Female
Ethnicity	White	White	Asian
Country of residence	United States	United States	Japan
Birth year	1943	1946	1942
Occupation	Teacher	Teacher	Housewife
Year of diagnosis (age [yr])	1996 (53)	1989 (43)	1997 (55)
Status	Alive	Alive	Alive
Follow-up (yr)	8	12	5
AMA	Positive	Positive	Negative
Symptoms	None	None	None
Latest histologic stage (I-IV)	II (2001)	II-III (1999)	II (1997)
Endoscopic signs of portal hypertension	None	Not done	None
Associated autoimmune conditions	None	Psoriasis	Type 2 diabetes mellitus

^aThe unaffected twins from these sets remain asymptomatic.

sites or levels of DNA methylation, can also interfere with the direct genotype-phenotype correlation. Indeed, epigenetics play a role in cell aging³⁴ and neoplasia³⁵ and could lead to the discordance observed between MZ twins. For example, based on the surprising data on the variable expression of the sheep *callipyge* gene,³⁶ efforts are now being dedicated to the study of imprinted human genes. Additional factors that might also potentially interfere with the classical model of zygosity in twins are chimerism and mosaicism; these pockets of genetically mismatched cells appear to be relatively frequent in both single and twin births, possibly due to the antenatal sharing of blood supply.³⁷ A role for chimerism and mosaicism has been suggested in a number of complex diseases, including autoimmune disorders.³⁸ Similarly, recently suggested acquired haplotype deficiencies of specific chromosomes³⁹ could also be involved in explaining the discordant cases encountered.

In autoimmune conditions other than PBC (such as systemic lupus erythematosus, type 1 diabetes mellitus, Graves' disease, systemic sclerosis, and rheumatoid arthritis), CRs among MZ twins have been found in cross-sectional studies to be generally <0.50 (Table 1). Some of these studies, however, showed that CR could often be increased by longer periods of follow-up of unaffected individuals.⁴⁰

Our population is the largest group of twins thus far described in PBC. There are, however, several limitations in our data. Firstly, of course, there is potential bias derived from enrollment. We note that this type of recruitment may be responsible for a higher prevalence of females, and that could lead to an overestimation of CR through an overascertainment of concordant pairs.^{41,42} Such biases could be reduced by twin studies based on national or local registries. However, the lack of a reliable register of patients with PBC (as the one recently used for celiac disease⁴³) and of a sensitive 100% reliable noninvasive marker of the disease (5%–15% of patients with PBC lack detectable AMA when tested by indirect immunofluorescence technique⁴) militate against this approach. Second, we note that longer observation periods will influence CRs; however, we note the long duration of follow-up of the discordant MZ sets described herein and, therefore, the consistent long-standing status of the unaffected twin. Finally, the data described herein show lower CR among MZ twins compared with our earlier abstract,⁴⁴ thus emphasizing the necessity of a comprehensive determination of zygosity. For example, one set of twins that was previously believed to be MZ and concordant for PBC turned out to be not twins at all but rather nontwin siblings.

The pairwise and proband-wise CRs for PBC in MZ twins described herein (Table 3) were found to be among the highest observed in cross-sectional twin studies on other autoimmune conditions except celiac disease (Table 1). This is a consistent finding with the relative risk factor for development of PBC within a family, which was also found to be the highest among autoimmune disease.¹³ Moreover, we found that both twins within concordant sets were diagnosed with PBC within a short period of time in all but one set (Table 4), although this could be due to the increased awareness related to the diagnosis of PBC in the twin presenting earlier signs of disease. It is also interesting to note that the clinical and biochemical characteristics were nearly identical in only 2 of 4 concordant MZ pairs. In one set (Table 4; set 2), 2 very different clinical history patterns were encountered. One individual has had a nonprogressing early-stage disease for more than a decade of follow-up, whereas her twin sister underwent orthotopic liver transplantation 8 years after diagnosis of end-stage PBC. No apparent difference in any environmental factor could be identified between the 2 sisters. In another set (set 5), different disease stages were encountered at liver histology, although we emphasize that the liver biopsy specimen showing stage I in patient A was performed 5 years before the histology showing stage II–III was available in patient B. Moreover, 2 slightly different patterns of autoimmunity were noted in another set (Table 4; set 1) in which both sisters presented positive AMA as well as antinuclear antibodies. In one case (set 1, A), histologic analysis showed a PBC/autoimmune hepatitis overlap, whereas only PBC was found in the other (set 1, B). We also note that 2 of 5 MZ twin pairs (sets 2 and 4) also presented concordant occurrence of sicca syndrome and hypothyroidism as accompanying conditions. We submit that the relatively small number of observations in this study might account for a type II error, possibly responsible for the lack of clinical difference observed in 2 of 5 concordant sets. In diseases as uncommon as PBC, these data still represent a significant number of patients.

The finding of this high degree of concordance seems to suggest that genetics play a major role in the induction of PBC. The possible confounding role for antenatal factors,³³ epigenetics,⁴⁵ or chimerism and mosaicism,³⁷ as previously discussed, could strengthen this assumption. Our data do not rule out the likelihood that environmental factors serve as a trigger, as observed in celiac disease, that presents a high CR in MZ twins and that shares, like PBC, both genetic and environmental etiologic factors.⁴⁶ We suggest that a vigorous study using, for example, inheritance by descent or linkage analysis, is

critical to determine the genetic basis of PBC. Nonetheless, the size of the PBC cohort represented by the 8 MZ sets described herein is representative, based on the variable reported prevalence rates of PBC, of approximately 5–100 million general population individuals. We encourage an international effort to develop a database on a larger number of twin sets or representative families with more than one member affected to define the genetic basis of PBC.

References

- Kaplan MM. Primary biliary cirrhosis. *N Engl J Med* 1996;335:1570–1580.
- Jones DE, Watt FE, Metcalf JV, Bassendine MF, James OF. Familial primary biliary cirrhosis reassessed: a geographically based population study. *J Hepatol* 1999;30:402–407.
- Parikh-Patel A, Gold E, Mackay IR, Gershwin ME. The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. *Clin Immunol* 1999;91:206–218.
- Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, Colvin ME, Lam KS, Coppel RL, Ansari A, Gershwin ME. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. *J Immunol* 2001;167:2956–2963.
- Tanaka A, Borchers AT, Ishibashi H, Ansari AA, Keen CL, Gershwin ME. Genetic and familial considerations of primary biliary cirrhosis. *Am J Gastroenterol* 2001;96:8–15.
- Chohan MR. Primary biliary cirrhosis in twin sisters. *Gut* 1973;14:213–214.
- Kaplan MM, Rabson AR, Lee YM, Williams DL, Montaperto PA. Discordant occurrence of primary biliary cirrhosis in monozygotic twins. *N Engl J Med* 1994;331:951.
- Friedrich C. More on primary biliary cirrhosis in monozygotic twins. *N Engl J Med* 1995;332:336.
- Metcalf JV, Howel D, James OF, Bhopal R. Primary biliary cirrhosis: epidemiology helping the clinician. *BMJ* 1996;312:1181–1182.
- Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. *Tissue Antigens* 1992;39:225–235.
- Emery AEH. *Methodology in medical genetics: an introduction to statistical methods*. Edinburgh, Scotland: Churchill Livingstone, 1986.
- MacGregor AJ. Practical approaches to account for biases and confounding in twin data. In: Spector TD, Snieder H, MacGregor AJ, eds. *Advances in twin and sib-pair analysis*. London, England: Greenwich Medical Media Ltd, 2000:35–52.
- Tsuji K, Watanabe Y, Van De Water J, Nakanishi T, Kajiyama G, Parikh-Patel A, Coppel R, Gershwin ME. Familial primary biliary cirrhosis in Hiroshima. *J Autoimmun* 1999;13:171–178.
- Miyamori H, Kato Y, Kobayashi K, Hattori N. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. *Digestion* 1983;26:213–217.
- Bassendine MF, Dewar PJ, James OF. HLA-DR antigens in primary biliary cirrhosis: lack of association. *Gut* 1985;26:625–628.
- Manns MP, Bremm A, Schneider PM, Notghi A, Gerken G, Prager-Eberle M, Stradmann-Bellinghausen B, Meyer zum Buschenfelde KH, Rittner C. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. *Gastroenterology* 1991;101:1367–1373.
- Moring N, Dalhoff K, Fugger L, Georgsen J, Jakobsen B, Ranek L, Odum N, Svejgaard A. DNA polymorphism of HLA class II genes in primary biliary cirrhosis. *Immunogenetics* 1992;35:112–116.
- Maeda T, Onishi S, Saibara T, Iwasaki S, Yamamoto Y. HLA DRw8 and primary biliary cirrhosis. *Gastroenterology* 1992;103:1118–1119.
- Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. *Hepatology* 1992;16:1404–1408.
- Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, Gershwin ME. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. *Tissue Antigens* 1994;43:71–77.
- Onishi S, Sakamaki T, Maeda T, Iwamura S, Tomita A, Saibara T, Yamamoto Y. DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. *J Hepatol* 1994;21:1053–1060.
- Mella JG, Roschmann E, Maier KP, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. *Hepatology* 1995;21:398–402.
- Underhill JA, Donaldson PT, Doherty DG, Manabe K, Williams R. HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis. *Hepatology* 1995;21:959–962.
- Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and Interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. *Gut* 2001;48:397–402.
- Wassmuth R, Depner F, Danielsson A, Hultcrantz R, Loof L, Olson R, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindgren S. HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. *Tissue Antigens* 2002;59:381–387.
- Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, De Arias AE, Scalamogna M, Zuin M, Podda M. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. *J Hepatol* 2003;38:401–406.
- Agarwal K, Jones DE, Bassendine MF. Genetic susceptibility to primary biliary cirrhosis. *Eur J Gastroenterol Hepatol* 1999;11:603–606.
- Gershwin ME. The natural history of primary biliary cirrhosis: of genes and cooperation. *J Hepatol* 2001;35:412–415.
- Selmi C, Zuin M, Meda F, Podda M, Biondi ML, Cecchini F. Common variants of the matrix metalloproteinase-3 (stromelysin) gene promoter in primary biliary cirrhosis. *Gastroenterology* 2002;122:247–248.
- Selmi C, Zuin M, Biondi ML, Invernizzi P, Battezzati PM, Bernini M, Meda F, Gershwin ME, Podda M. Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: association with disease severity. *J Gastroenterol Hepatol* 2003;18:1150–1155.
- Bortolus R, Parazzini F, Chatenoud L, Benzi G, Bianchi MM, Marini A. The epidemiology of multiple births. *Hum Reprod Update* 1999;5:179–187.
- Haegert DG, Galutira D, Murray TJ, O'Connor P, Gadag V. Identical twins discordant for multiple sclerosis have a shift in their T-cell receptor repertoires. *Clin Exp Immunol* 2003;134:532–537.
- Gringras P, Chen W. Mechanisms for differences in monozygous twins. *Early Hum Dev* 2001;64:105–117.
- Bandyopadhyay D, Medrano EE. The emerging role of epigenetics in cellular and organismal aging. *Exp Gerontol* 2003;38:1299–1307.
- Feinberg AP, Tycko B. Timeline: the history of cancer epigenetics. *Nat Rev Cancer* 2004;4:1–11.
- Georges M, Charlier C, Cockett N. The callipyge locus: evidence for the transinteraction of reciprocally imprinted genes. *Trends Genet* 2003;19:248–252.

37. Pearson H. Dual Identities. *Nature* 2002;417:10-11.
38. Nelson JL. Microchimerism: incidental byproduct of pregnancy or active participant in human health? *Trends Mol Med* 2002;8:109-113.
39. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, Selmi C, Watnik M, Gershwin ME, Podda M. Frequency of monosomy X in women with primary biliary cirrhosis. *Lancet* 2004;363:533-535.
40. Verge CF, Gianani R, Yu L, Pietropaolo M, Smith T, Jackson RA, Soeldner JS, Eisenbarth GS. Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type 1 diabetes. *Diabetes* 1995;44:1176-1179.
41. Hawkes CH. Twin studies in diabetes mellitus. *Diabet Med* 1997;14:347-352.
42. Rowe RE, Leslie RD. Twin studies in insulin dependent diabetes and other autoimmune diseases. *Diabetes Metab Rev* 1995;11:121-135.
43. Greco L, Romino R, Coto I, Di Cosmo N, Percopo S, Maglio M, Paparo F, Gasperl V, Limongelli MG, Cotichini R, D'Agate C, Tinto N, Sacchetti L, Tosi R, Stazi MA. The first large population based twin study of coeliac disease. *Gut* 2002;50:624-628.
44. Selmi C, Mayo MJ, Bach N, Gish RG, Wright HI, Ishibashi H, Gordon SC, Invernizzi P, Seldin MF, Podda M, Gershwin ME. Occurrence of primary biliary cirrhosis in monozygotic twins (abstract). *Hepatology* 2002;36:387A.
45. Singh SM, Murphy B, O'Reilly R. Epigenetic contributors to the discordance of monozygotic twins. *Clin Genet* 2002;62:97-103.
46. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. *Nat Rev Immunol* 2002;2:647-655.
47. Quigley EM, LaRusso NF, Ludwig J, MacSween RN, Birnie GG, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. *Gastroenterology* 1983;85:1160-1165.
48. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM. A revised estimate of twin concordance in systemic lupus erythematosus. *Arthritis Rheum* 1992;35:311-318.
49. Bolstad AI, Haga HJ, Wassmuth R, Jonsson R. Monozygotic twins with primary Sjögren's syndrome. *J Rheumatol* 2000;27:2264-2266.
50. Kumar D, Gemayel NS, Deapen D, Kapadia D, Yamashita PH, Lee M, Dwyer JH, Roy-Burman P, Bray GA, Mack TM. North-American twins with IDDM. Genetic, etiological, and clinical significance of disease concordance according to age, zygosity, and the interval after diagnosis in first twin. *Diabetes* 1993;42:1351-1363.
51. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. *BMJ* 1995;311:913-917.
52. Hawa M, Rowe R, Lan MS, Notkins AL, Pozzilli P, Christle MR, Leslie RD. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. *Diabetes* 1997;46:1270-1275.
53. Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. *J Rheumatol* 1986;13:899-902.
54. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. *Br J Rheumatol* 1993;32:903-907.
55. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis Rheum* 2000;43:30-37.
56. Ringold DA, Nicoloff JT, Kesler M, Davis H, Hamilton A, Mack T. Further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. *Thyroid* 2002;12:647-653.
57. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. *J Clin Endocrinol Metab* 2001;86:930-934.
58. Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH, Compston DA. The British Isles survey of multiple sclerosis in twins. *Neurology* 1994;44:11-15.
59. Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW, Hashimoto SA, Warren S, Hader W, Murray TJ, et al. A population-based study of multiple sclerosis in twins: update. *Ann Neurol* 1993;33:281-285.
60. Hervonen K, Karell K, Holopainen P, Collin P, Partanen J, Reunala T. Concordance of dermatitis herpetiformis and celiac disease in monozygous twins. *J Invest Dermatol* 2000;115:990-993.

Received February 10, 2004. Accepted April 29, 2004.

Address requests for reprints to: M. Eric Gershwin, M.D., Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, TB 192, Davis, California 95616. e-mail: megershwin@ucdavis.edu; fax: (530) 752-4669.

Supported by National Institutes of Health grant 39588.

The authors thank Joseph Schauer (Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Davis, CA) for STRs typing and Drs. Peter Stastny and Robert Vorhaben (Histocompatibility Laboratory, Transplant Immunology Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX) for HLA typing.

Biliary Epithelial Cells Regulate Autoreactive T Cells: Implications for Biliary-Specific Diseases

Takashi Kamihira,¹ Shinji Shimoda,¹ Minoru Nakamura,² Teruhumi Yokoyama,² Yasushi Takii,^{1,2} Akira Kawano,¹ Mizuki Handa,¹ Hiromi Ishibashi,² M. Eric Gershwin,³ and Mine Harada¹

The biliary epithelial cell (BEC) is the target for several human immune mediated liver diseases, including primary biliary cirrhosis, but it is not always clear whether the BEC functions as an accessory cell or an antigen presenting cell, although it is well documented that BECs express high levels of human leukocyte antigen Class II, intercellular adhesion molecule-1, and lymphocyte function-associated antigen-3. To examine this issue, we established autoreactive T-cell clones from human leukocyte antigen-DR53 patients with primary biliary cirrhosis and characterized BEC function as a function of the ability of BECs to regulate T-cell activation. We report herein that BEC-mediated T-cell activation occurs partially via programmed death 1 ligands in a cell-contact-dependent manner. Further, such activation occurs via prostaglandin E2 production in a cell-contact-independent fashion. Moreover, the production of prostaglandin E2 was partially controlled by interleukin-1 β and tumor necrosis factor α . **In conclusion**, the regulatory activities of BECs are important for the maintenance of peripheral immune tolerance. Further, modulation of BEC function may be used for therapeutic modulation. (HEPATOLOGY 2005;41:151–159.)

The biliary epithelial cell (BEC) is the target lesion of several enigmatic human immunologically mediated liver diseases, including primary biliary cirrhosis (PBC), but it is unclear whether the biliary epithelium is the innocent victim of an immune attack or whether it participates actively as either an accessory cell (AC) or as an antigen-presenting cell (APC). One explanation for the vulnerability of BECs in PBC and other cholestatic pathology to immune attack is their

relatively high expression of human leukocyte antigen (HLA) class I, HLA class II, intercellular adhesion molecule-1, and lymphocyte function-associated antigen-3.^{1–7} In PBC, BECs also express B7 molecules.^{8,9} Further, following *in vitro* stimulation with the proinflammatory cytokines (*i.e.*, interferon γ [IFN γ]), BECs express HLA class I, HLA class II, intercellular adhesion molecule-1, lymphocyte function-associated antigen-3, and CD40.^{10,11} In addition, BECs produce chemokines, including interleukin (IL)-8, monocyte chemoattractant protein-1, and stromal cell-derived factor-1.^{12–14} Thus, while BECs are the targets of immune attack, they may also be actively involved in the regulation of peripheral immunity.

We have previously reported the characteristics of different classes of autoreactive T-cell clone (TCC). One type of clone-recognized antigen (Ag) in a costimulation-independent manner while the other, in contrast, was costimulation dependent. Further, we demonstrated that BECs from patients with PBC do not function as APCs to either of these autoreactive TCCs. In fact, our data illustrated that BECs regulate the proliferation of costimulation-dependent TCCs after rendering them anergic.¹⁵ This latter finding was unique and led us to investigate the mechanism of this regulatory effect of BECs in detail. We report herein that BECs regulate autoreactive T cells even in the presence of professional APCs through the direct action of several inhibitory molecules, including ligands of programmed death 1 (PD-1)

Abbreviations: BEC, biliary epithelial cell; PBC, primary biliary cirrhosis; AC, accessory cell; APC, antigen-presenting cell; HLA, human leukocyte antigen; IFN γ , interferon γ ; IL, interleukin; TCC, T-cell clone; Ag, antigen; PD-1, programmed death 1; PD-L1, programmed death 1 ligand 1; PD-L2, programmed death 1 ligand 2; PG-E2, prostaglandin E2; PBMC, peripheral blood mononuclear cell; PCR, polymerase chain reaction; TNF α , tumor necrosis factor α ; LPS, lipopolysaccharide; Ab, antibody; TGF β , transforming growth factor β .

From the ¹Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; ²National Nagasaki Medical Center, Omura, Japan; and ³Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California Davis, Davis, CA.

Received July 10, 2004; accepted September 23, 2004.

Supported by grants-in-aid from the Ministry of Health, Labour and Welfare and from the Ministry of Education, Culture, Sports, Science and Technology of Japan and National Institutes of Health grants DK39588 and DK92310.

Address reprint requests to: Shinji Shimoda, M.D., Ph.D., Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan. E-mail: sshimoda@intmed.med.kyushu-u.ac.jp; fax: (81) 92-642-5247.

Copyright © 2004 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.20494

Conflict of interest: Nothing to report.

(PD-1 ligands 1 and 2 [PD-L1 and PD-L2]) and through the indirect action of prostaglandin E2 (PG-E2). We postulate that the regulatory role of BECs on autoreactive T cells is important for the maintenance of peripheral immune tolerance in the portal area.

Materials and Methods

Generation of Autoreactive TCCs That Respond to Human PDC-E2 163-176. Using methods previously described,¹⁵ we isolated and characterized 2 human autoreactive TCCs, coined HT7 and HK15, from 2 HLA-DR53 patients with early-stage PBC. Peripheral blood mononuclear cells (PBMCs) from these 2 patients were placed in RPMI medium containing 10% fetal calf serum and repeatedly stimulated by PDC-E2 163-176-pulsed irradiated autologous PBMCs. The 2 PDC-E2 163-176-specific TCCs were established by limiting dilution. These 2 TCCs were CD3⁺, CD4⁺, CD8⁻, CD45RO⁺, and TCR $\alpha\beta$ ⁺ and produced a Th1-type cytokine profile, expressing high levels of IFN γ and low levels of IL-4, and recognized PDC-E2 163-176 in an HLA-DR53-restricted manner.¹⁵ Both clones recognize amino acids 163-176 (GDLLAEIETDKATI) in PDC-E2 within the context of HLA-DR53. The antigenic peptide used in this study, PDC-E2 163-176, was synthesized on a solid phase simultaneous multiple peptide synthesizer (PSSM-8, Shimadzu, Kyoto, Japan), based on previously described Fmoc strategy.¹⁶

Generation of Human Intrahepatic BEC Lines. We simultaneously established BEC lines from human liver obtained at the time of orthotopic liver transplantation, using tissue derived from 3 different HLA DR53-positive patients with either end-stage PBC or other liver disease.^{11,17} Briefly, liver specimens were digested with collagenase type IV (Sigma, St. Louis, MO); the digested cells were then harvested. BECs were immunomagnetically separated using Dynabeads-conjugated BerEp4 (DynaL Biotech, Brown Deer, WI), an epithelium-specific antibody. Cells were resuspended in complete BEC medium (a 1:1 mixture of Ham's F12 and DMEM, supplemented with 5% fetal calf serum, epithelial growth factor [10 ng/mL], cholera toxin [10 ng/mL], hydrocortisone [0.4 μ g/mL], tri-iodo-thyronine [1.3 μ g/L], transferrin [5 μ g/mL], insulin [5 μ g/mL], adenine [24.3 μ g/mL] [Sigma], and hepatocyte growth factor [10 ng/mL] [R&D Systems, Minneapolis, MN], was then seeded in 12-well plates. The BECs were passaged before confluence. Importantly, the isolated cells were positive by immunohistochemistry for cytokeratin 7 and cytokeratin 19 (using specific antibodies obtained from Dako [Carpinteria, CA]) and immunoperoxidase detection. These criteria

defined these cells as the BEC phenotype. Purified cells were greater than 99% pure, and the cultures used in the studies herein were between 4 to 6 passages.

Flow Cytometry. To analyze surface expression of costimulatory molecules, BECs were stained by indirect immunofluorescence using anti-HLA-DR (Becton Dickinson, San Jose, CA), anti-PD-L1 (R&D Systems) and anti-PD-L2 (Genzyme, Cambridge, MA). TCCs were stained by indirect immunofluorescence using anti-PD-1 (Becton Dickinson, Franklin Lakes, NJ). Dilutions of each antibodies were 10 μ g/mL. Known positive and negative cells were used in parallel, and stained cells were analyzed on a FACScan (Becton Dickinson).

Isolation of Messenger RNA and Reverse-Transcriptase Polymerase Chain Reaction (PCR). BECs were cultured in 6-well plates for 0, 2, 4, 8, or 24 hours in the presence of IFN γ (1,000 U/mL), tumor necrosis factor α (TNF α) (1,000 U/mL), or lipopolysaccharide (LPS) (1 μ g/mL). Total RNA was extracted from cultured BECs using an RNeasy kit (QIAGEN, Hilden, Germany) and the isolated RNA stored at -80°C. First-strand complementary DNA synthesis was performed with 5 μ g of total RNA as a template using SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA). Quantitative PCR of first-strand complementary DNAs were performed using a LightCycler with gene-specific primer pairs of GADPH (Roche, Indianapolis, IN) as a control. After quantitation of GADPH contents, each sample was diluted to equalize the concentration of GADPH. PCR for PD-L1 and PD-L2 were thence performed with gene-specific custom primer pairs (Sigma Genosys, St. Louis, MO); the conditions for amplification were 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 45 seconds, and extension at 72°C for 45 seconds. PCR products were resolved on a 1.5% agarose gel containing ethidium bromide. Gels were visualized under ultraviolet light and photographed. To reconfirm that BECs had a biliary phenotype and had lost a hepatocyte phenotype, PCR for albumin and alpha-fetoprotein were thence performed with gene-specific custom primer pairs (Sigma Genosys). The HepG2 cell line was used as positive control for albumin and alpha-fetoprotein.

Antigen Presenting Activity of s, HLA-DR53 Transfected Mouse L Fibroblasts, or BECs. T-cell proliferation was assayed by culturing the TCCs (5×10^4 /well) with APCs in a 96-well plate for 72 hours. During the final 16 hours of culture, 0.5 μ Ci/well ³H-thymidine was added. IFN γ -treated BECs (2×10^4), irradiated PBMC (2×10^5), or mitomycin C-treated HLA-DR53 transfected mouse L fibroblasts (2×10^4) were used as APC after pulsing with PDC-E2 163-176 peptide. Following cell harvest, ³H-thymidine uptake was measured in a beta

Table 1. Thymidine Incorporation and PG-E2 Production of Coculture Experiments

		³ H-TdR* (cpm)	PG-E2† (pg/mL)
#1	BEC	13,879 ± 350	87 ± 23
#2	TCC	12,928 ± 264	79 ± 31
#3	TCC, Ag-nonpulsed PBMC	15,462 ± 122	203 ± 37
#4	TCC, Ag-pulsed PBMC	16,803 ± 43	407 ± 9
#5	BEC and TCC, Ag-nonpulsed PBMC	12,239 ± 92	213 ± 115
#6	BEC and TCC, Ag-pulsed PBMC	5,219 ± 1,628	44,333 ± 8,956
#7	BEC cocultured with supernatant of #3	12,330 ± 1,628	293 ± 34
#8	BEC cocultured with supernatant of #4	5,415 ± 428	46,666 ± 4,988

NOTE. Data points represent mean ± SD of triplicate cultures. BECs were preincubated with IFN γ .

*The supernatant of combined culture medium was added to the T-cell proliferation assay. $P < .001$ when compared #1 to #6, #3 to #6, #4 to #6; $P < .01$ when compared #2 to #6, #5 to #6, #7 to #6, #7 to #8; $P < .0001$ when compared #1 to #8, #2 to #8, #3 to #8, #4 to #8, #5 to #8; $P = .85$ when compared #6 to #8.

†The supernatant of combined culture medium was measured. $P < .01$ when compared #1 to #6, #2 to #6, #3 to #6, #4 to #6, #5 to #6; $P < .0001$ when compared #7 to #8.

scintillation counter. In specific experiments, anti-PD-L1 antibody (Ab) (10 μ g/mL) or anti-PD-L2 Ab (10 μ g/mL) (eBioscience, San Diego, CA) was used to block the effect of PD-L1 or PD-L2, respectively. For anti-PD-L1 Ab and anti-PD-L2 Ab, BECs were precultured with these antibodies for 30 minutes before removing excess antibody by washing prior to T-cell addition.

Transwell Assay. To assess the dependence of BEC regulation of T-cell activation on cell contact, transwell assays were performed using cell culture inserts (0.4- μ m pore size; Becton Dickinson). Ag-pulsed irradiated PBMCs (3,000 rad) (1×10^6) and TCCs (5×10^5) were cocultured in the lower compartment of a 24-well plate, while BECs (1×10^5) were added to the lower or the upper compartment as accessory cells. Cells were then cultured for 72 hours; 0.5 μ Ci/well ³H-thymidine was added to the cultures for the final 16 hours. ³H-thymidine uptake was measured in a beta scintillation counter.

The Effect of BECs as ACs and the Effect of Supernatants From BECs. A T-cell proliferation was assayed by culturing TCCs (5×10^4 /well) with PDC-E2 163-176 peptide pulsed or control (not pulsed) irradiated PBMCs (2×10^5) in a 96-well plate for 72 hours. During the final 16 hours of culture, 0.5 μ Ci/well ³H-thymidine was added. Following cell harvest, ³H-thymidine uptake was measured in a beta scintillation counter. To assess the effect of BECs as ACs on the proliferation of T cells, BECs (5×10^3) or BEC-cultured supernatants were added to this assay. In nested experiments, indomethacin (1 μ g/mL) (Sigma), anti-transforming growth factor β (TGF β) Ab (10 μ g/mL) (R&D Systems), anti-IL-10 Ab (10 μ g/mL) (R&D Systems), or NG-monomethyl-L-arginine (1 mmol/L) (Wako, Richmond, VA) were used to block the effect of PG-E2, TGF β , IL-10, and nitric oxide, respectively. To assess the effect of supernatant of BECs on the proliferation of T cells, the supernatant of the combination of TCCs (5×10^5), PBMCs (1×10^6) and BECs

(1×10^5) was added to the T-cell proliferation assay. Combined cells were cultured in 500 μ L RPMI containing 10% fetal calf serum for 72 hours in a 24-well plate, and the supernatant was filtered and mixed 1:2 to the T-cell proliferation assay. The schema and groups used are shown in Table 1: (#1) BECs cultured alone; (#2) TCCs cultured alone; (#3) BECs cultured with nonantigen pulsed PBMCs; (#4) BECs cultured with Ag-pulsed PBMCs; (#5) BECs cultured with nonantigen pulsed PBMCs and TCCs; (#6) BECs cultured with Ag-pulsed PBMCs and TCCs; (#7) BECs cultured with supernatant of 36 hours cultured nonpulsed PBMCs and TCCs; or (#8) BECs cultured with supernatant of 36 hours cultured Ag-pulsed PBMCs and TCCs.

Quantitation of Cytokines, PG-E2, and Nitric Oxide. BECs (1×10^5) were cocultured in 500 μ L RPMI containing 10% fetal calf serum in 24-well plates for 72 hours alone, with TCCs (5×10^5) and control Ag nonpulsed PBMCs (1×10^6) or with TCCs (5×10^5) and Ag (10 μ g/mL) pulsed PBMCs (1×10^6), as described in Table 1. When specified, BECs were cultured with recombinant human IFN γ (1,000 U/mL) (Sigma), TNF α (1,000 U/mL), IL-1 β (10 ng/mL) (Strathmann Biotech GmbH, Hannover, Germany), or LPS (1 μ g/mL) (Sigma). BECs were also cultured in the presence of supernatants of TCCs and Ag-pulsed PBMCs with or without neutralizing anti-TNF α , anti-IL-1 β , control immunoglobulin G (Genzyme), or indomethacin. TGF β (R&D Systems), IFN γ , IL-10, TNF α (Japan Immunoresearch Laboratories Co., Gunma, Japan), IL-1 β (BioSource Europe, Nivelles, Belgium), and PG-E2 (Amersham Life Science, Piscataway, NJ) from the culture supernatants were measured by enzyme-linked immunosorbent assays. The production of nitric oxide was estimated by measuring the amount of nitrite using the Griess reagent (Wako).¹⁸

Results

Characterization of BECs. Three BEC lines were used herein from 3 HLA-DR53-positive patients, 1 with PBC and 2 with HCV-positive cirrhosis. The 3 BEC lines gave similar data. As determined by reverse-transcriptase PCR, BECs have a biliary phenotype (Fig. 1A). As determined by flow cytometry, BECs did not express HLA-DR, while IFN γ -treated BECs expressed HLA-DR. BECs expressed the inhibitory molecules, PD-L1 and PD-L2, the ligands of PD-1, and TCCs expressed PD-1 (Fig. 1B). BECs also manifest messenger RNA encoding PD-L1 and PD-L2; the expression of which peaked at 2 to 8 hours after IFN γ treatment, as determined by semi-quantitative PCR (Fig. 1C). Expression of PD-L1 and PD-L2 were also upregulated after treatment with either TNF α or LPS (Fig. 1C).

BECs Do Not Induce Proliferation of TCCs. To assess the ability of HLA-DR-expressing BECs to function as APCs, our costimulation independent or dependent auto Ag specific TCCs were cultured with IFN γ -treated BECs for 72 hours. Both costimulation independent HT7 and dependent HK15 proliferated when cocultured with Ag-pulsed HLA-DR53-positive PBMCs ($18,060 \pm 1,033$ and $14,036 \pm 2,220$ cpm) as professional APCs. However, HT7, but not HK15, proliferated when cocultured with Ag-pulsed L-DR53 ($21,203 \pm 1,211$ and 166 ± 32 cpm) (Fig. 2A-B). Both costimulation independent HT7 and dependent HK15 did not proliferate in response to Ag-pulsed IFN γ -treated BECs expressing HLA-DR53 (155 ± 32 and 154 ± 29 cpm) (Fig. 2A-B). These results indicate that BECs do not function as professional APCs to induce T-cell activation. To determine the mechanism of BEC-mediated T-cell inhibition, TCCs were cocultured with Ag pulsed BECs in the presence of anti-PD-L1 or anti-PD-L2 blocking antibodies. Costimulation-dependent HK15 did not proliferate in the presence of anti-PD-L1 (422 ± 33 cpm) or anti-PD-L2 (491 ± 9 cpm) blocking antibodies (Fig. 2B). In contrast, costimulation independent HT7 could be partially activated using the combination of both anti-PD-L1 and anti-PD-L2 antibodies ($5,765 \pm 123$ cpm) during coculture with Ag-pulsed BECs ($P = .0002$, compared with anti-PD-L1, $P < .0001$, compared with anti-PD-L2) (Fig. 2A). These data indicate that HLA-DR-expressing BECs regulate T-cell activation, partially due to the expression of PD-L1 and PD-L2, which are the ligands of PD-1 of T cells.

BECs as ACs Regulate T Cells in a Cell-Contact-Independent Manner. To further assess the effect of BECs, TCCs were cultured with Ag-pulsed irradiated PBMCs as APCs in the presence or absence of BECs as ACs




Fig. 1. Demonstration of biliary epithelial cell (BEC) phenotype, including the expression of human leukocyte antigen (HLA)-DR, programmed death 1 ligand 1 (PD-L1), and programmed death 1 ligand 2 (PD-L2) on BECs and the expression of programmed death 1 (PD-1) on T-cell clones (TCCs). (A) The expression of messenger RNA in BECs and the HepG2 cell line encoding albumin (Alb) and alpha-fetoprotein (AFP) was assessed by semi-quantitative reverse-transcriptase polymerase chain reaction. The expression of messenger RNA encoding Alb and alpha-fetoprotein was detected in HepG2 but not in BECs. (B) Surface expression of HLA-DR, PD-L1, and PD-L2 on BECs was assessed by flow cytometry. Nontreated BECs (shaded histograms) did not express HLA-DR, while interferon γ (IFN γ) treatment (open histograms) upregulated HLA-DR. PD-L1 and PD-L2 were constantly expressed on IFN γ -treated or control (nontreated) BECs. PD-1 was expressed on TCCs regardless of their costimulation dependency. (C) The expression of messenger RNA in BECs encoding PD-L1 and PD-L2 was assessed by semi-quantitative reverse-transcriptase polymerase chain reaction after treatment with IFN γ , tumor necrosis factor α or lipopolysaccharide for 0, 2, 4, 8, and 24 hours. The expression of messenger RNA encoding PD-L1 and PD-L2 was upregulated as early as 2 hours after stimulation, reaching a maximum at 4 to 8 hours after IFN γ , tumor necrosis factor α , or lipopolysaccharide treatment.